Search results for "proBNP"

showing 10 items of 13 documents

Cardiac risk stratification in elective non-cardiac surgery: Role of NT-proBNP

2011

AIM: The aim of the study was to investigate the utility of NT-proBNP measurement for the stratification of presurgical cardiac risk. METHODS: Cardiac risk before elective non-cardiac surgery was evaluated in 82 consecutive patients. From each patient a venous blood sample was drawn to determinate NT-proBNP levels. Patients were followed up over three months in order to detect the occurrence of cardiac adverse events. RESULTS: NT-proBNP was positively correlated (P<0.0001) with age, days of hospitalization (P=0.001) and ASA class (P=0.001). High surgical risk (P<0.0001), diabetes (P=0.004), dyslipidemia (P=0.006) and elevated levels of NT-proBNP (P<0.0001) were significantly correlated with…

MaleChi-Square DistributionTime FactorsMiddle AgedRisk AssessmentPeptide FragmentsUp-RegulationLogistic ModelsTreatment OutcomeItalyNT-proBNPCardiovascular DiseasesElective Surgical ProceduresPredictive Value of TestsRisk FactorsSurgical Procedures OperativeNatriuretic Peptide BrainPreoperative PeriodOdds RatioHumansFemaleBiomarkersAged
researchProduct

Cardiorenal Syndrome: New Pathways and Novel Biomarkers

2021

Cardiorenal syndrome (CRS) is a multi-organ disease characterized by the complex interaction between heart and kidney during acute or chronic injury. The pathogenesis of CRS involves metabolic, hemodynamic, neurohormonal, and inflammatory mechanisms, and atherosclerotic degeneration. In the process of better understanding the bi-directional pathophysiological aspects of CRS, the need to find precise and easy-to-use markers has also evolved. Based on the new pathophysiological standpoints and an overall vision of the CRS, the literature on renal, cardiac, metabolic, oxidative, and vascular circulating biomarkers was evaluated. Though the effectiveness of different extensively applied biomark…

kidneyrenal injuryDiseaseCardiorenal syndromeReviewheartBioinformaticsBiochemistryMicrobiologyPathogenesisRenal injuryotorhinolaryngologic diseasesMedicineHumansNGALKIM-1Molecular Biologycardiorenal syndromeKidneymicroRNACardio-Renal Syndromebusiness.industryAcute kidney injuryChronic injurymedicine.diseasechronic renocardiac syndromenovel biomarkersPrognosisQR1-502proBNPCirculating biomarkersmedicine.anatomical_structureacute kidney injurybusinessAcute kidney injury; Cardiorenal syndrome; Chronic renocardiac syndrome; Heart; Kidney; KIM-1; MicroRNA; NGAL; Novel biomarkers; ProBNP; Renal injuryBiomarkersBiomolecules
researchProduct

Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure

2020

Background: Plasma amino-terminal pro-B-type natriuretic peptide and antigen carbohydrate 125 levels are positively associated with a higher risk of adverse clinical outcomes in acute heart failure. As a proxy of congestion, antigen carbohydrate 125 has also been proposed as a right-sided heart failure marker. Thus, we aimed to determine in this population the main factors – including echocardiographic right-sided heart failure parameters – associated with antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide. Methods and results: We prospectively included 2949 patients admitted with acute heart failure. Amino-terminal pro-B-type natriuretic peptide and antigen carbohy…

Malemedicine.medical_specialtymedicine.drug_classacute heart failureAmino terminalCa 125 antigen030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineAntigenInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineProspective Studiesright-sided heart failureProtein PrecursorsAgedHeart Failurebusiness.industryGeneral MedicineCarbohydratemedicine.diseasePrognosisPeptide FragmentsEndocrinologyEchocardiographyNT-proBNPHeart failureCA-125 AntigenAcute DiseaseDisease ProgressionFemaleAntigen carbohydrate 125Cardiology and Cardiovascular MedicinebusinessRight-sided heart failureBiomarkersFollow-Up Studies
researchProduct

Analysis of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes

2009

Background The N-terminal portion of brain natriuretic peptide (NT-proBNP) has been identified as an indicator of prognosis in different cardiovascular diseases. The objective of this study was to determine the utility of measuring plasma NT-proBNP levels in patients with acute coronary syndromes. Methods and results We studied 66 patients admitted in our division for acute coronary syndromes. Patients underwent a venous blood sample within 24 h from the admission to determine NT-proBNP levels. Increasing plasma levels of NT-proBNP (in tertiles) was associated with a greater history of hypertension and current smoking, whereas biochemical parameters were associated with higher level of crea…

Malemedicine.medical_specialtymedicine.drug_classCreatineRisk AssessmentVentricular Dysfunction Leftchemistry.chemical_compoundPredictive Value of TestsRecurrenceNt-proBNP N-terminal pro-B-type natriuretic peptide acute coronary sydromeInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideCreatine Kinase MB FormHumansIn patientHospital MortalityAcute Coronary SyndromeAgedInpatientsCreatininebiologybusiness.industryTroponin IGeneral MedicineLength of StayMiddle AgedPrognosisBrain natriuretic peptidePeptide FragmentschemistryCreatininePredictive value of testsCardiologybiology.proteinFemaleCreatine kinaseN terminal pro b type natriuretic peptideCardiology and Cardiovascular MedicinebusinessBiomarkersCoronary Artery Disease
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure

2021

INTRODUCTION: We aimed to evaluate the trajectory of two surrogates of fluid overload -antigen carbohydrate 125 (CA125) and amino-terminal pro-brain natriuretic peptide (NT-proBNP)- after the addition of oral empagliflozin to usual care in a cohort of patients with chronic heart failure (CHF) and type 2 diabetes (T2D). METHODS AND RESULTS: From October 2015 to February 2019, 60 ambulatory patients with CHF and T2D were retrospectively included. The primary endpoint was to assess the longitudinal trajectory of plasma levels of CA125 and NT-proBNP after empagliflozin initiation. Changes in quantitative variables were evaluated using linear mixed regression. Median CA125 and NT-proBNP at basel…

medicine.medical_specialtyendocrine system diseasesType 2 diabetes030204 cardiovascular system & hematologyCA12503 medical and health sciences0302 clinical medicineGlucosidesEmplagliflozinInterquartile rangeLongitudinal trajectoriesInternal medicineNatriuretic Peptide BrainmedicineEmpagliflozinClinical endpointHumansSGLT2icardiovascular diseases030212 general & internal medicineBenzhydryl CompoundsRetrospective StudiesHeart FailureSurrogate endpointbusiness.industrymedicine.diseasePeptide FragmentsDiabetes Mellitus Type 2Heart failureNTproBNPAmbulatoryCohortCardiologyCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

Is the Serum N Terminal Pro-Brain Natriuretic Peptide the Best Candidate Biomarker for Long-term Prognosis in Patients with Prosthesis-patient Mismat…

2014

AGE8. Is the Serum N Terminal Pro-Brain Natriuretic Peptide the Best Candidate Biomarker for Long-term Prognosis in Patients with Prosthesis-patient Mismatch after Mitral Valve Replacement? C. R. Balistreri1, C. Pisano1, R. Franchino1, S.R. Vacirca1, F. Crapanzano1, O. F. Triolo1, C. Palmeri1, G. Ruvolo1 1University Of Palermo, Palermo, Italy Background: Natriuretic peptides (NPs) are released from the heart in response to pressure and volume overload. Among these, B-NP and Nterminal- proBNP (NT-proBNP) have become important diagnostic tools for the management of heart failure. However, B-NP and NT-proBNP levels reflect complications of systolic and diastolic function as well as alteration …

Natriuretic peptides (NPs) B-NP and Nterminal- proBNP (NT-proBNP) prosthesis patient mismatch (PPM) mitral valve replacement (MVR)
researchProduct

CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

2021

Abstract Background Intrarenal venous flow (IRVF) measured by Doppler ultrasound has gained interest as a potential surrogate marker of renal congestion and adverse outcomes in heart failure. In this work, we aimed to determine if antigen carbohydrate 125 (CA125) and plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with congestive IRVF patterns (i.e., biphasic and monophasic) in acute heart failure (AHF). Methods and results We prospectively enrolled a consecutive cohort of 70 patients hospitalized for AHF. Renal Doppler ultrasound was assessed within the first 24-h of hospital admission. The mean age of the sample was 73.5 ± 12.3 years; 47.1% were female, and…

medicine.medical_specialtymedicine.drug_classCarbohydrates030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVenous flow03 medical and health sciencesCA1250302 clinical medicineInterquartile rangeIntrarrenal Doppler ultrasoundInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineHeart FailureOriginal Scientific PaperSurrogate endpointbusiness.industryCardiorenalMembrane ProteinsAcute heart failureGeneral Medicinemedicine.diseasePrognosisPeptide FragmentsROC CurveHeart failureCA-125 AntigenCohortNTproBNPCardiologyCongestionFemaleDoppler ultrasoundCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkers
researchProduct

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure.

2016

Altres ajuts: Fundació La Marató de TV3 (no.201502-30), Sociedad Española de Cardiología, Societat Catalana de Cardiologia Despite advances in pharmacologic therapy and devices, patients with heart failure (HF) continue to have significant rehospitalization rates and risk prediction remains challenging. We sought to explore the value of a multi-biomarker panel [including NT-proBNP, high-sensitivity cardiac troponin T (hs-TnT), and ST2] on top of clinical assessment for long-term prediction of recurrent hospitalizations in HF. NT-proBNP, hs-TnT, and ST2 (suppression of tumorigenicity-2) levels were measured in 891 consecutive ambulatory HF patients. The independent association between the mu…

lcsh:Diseases of the circulatory (Cardiovascular) systemPediatricsmedicine.medical_specialtyCrude incidenceheart failureHeart failure030204 cardiovascular system & hematologyCardiovascular Medicine03 medical and health sciences0302 clinical medicineInternal medicineMedicinePharmacologic therapy030212 general & internal medicinehospitalizationsOriginal ResearchHospitalizationsbusiness.industrybiomarkerspredictionmedicine.diseaseST2lcsh:RC666-701NT-proBNPHeart failureAmbulatoryBiomarker (medicine)hs-TnTbusinessCardiology and Cardiovascular MedicinePredictionBiomarkersHs-tntFrontiers in cardiovascular medicine
researchProduct

Short term prognostic role of NT-proBNP in patients after myocardial infarction

2009

Aim. The clinical and prognostic role of cardiac natriuretic peptides (CNP) in patients with heart failure is well known; recently, several studies have evaluated the possibility of using CNP to evaluate their potential prognostic role in patients with acute coronary syndromes (ACS). The aim of this study was to evaluate the short term prognostic value of NT-proBNP in 70 patients admitted for ACS. Methods. The authors studied 70 patients with ACS, evaluating, at admission, clinical-anamnestic, instrumental and laboratory characteristics including NT-proBNP plasma levels. Patients were monitored in a 6-month-follow-up to record adverse fatal events and their possible correlation with baselin…

MaleTime FactorsMyocardial InfarctionMiddle AgedPrognosisSettore MED/11 - Malattie Dell'Apparato CardiovascolareNT-proBNP myocardial infarctionPeptide FragmentsLogistic ModelsPredictive Value of TestsRisk FactorsNT-proBNPNatriuretic Peptide BrainHumansFemaleBiomarkersAgedFollow-Up StudiesRetrospective Studies
researchProduct